Skip to Main Content

Nikolai Podoltsev, MD, PhD

Associate Professor of Internal Medicine (Hematology); Duffy Firm Chief for Education, Department of Internal Medicine; Associate Director of the Hematology/Oncology Fellowship Program

Research Summary

My research interests include management of malignant hematology conditions such as acute leukemias (focus on treatment of adults with ALL and AML patients with FLT-3 mutations), myelodysplastic syndromes (MDS) and myeloprolipherative neoplasms (MPN) as well as bone marrow failure (aplastic anemia) and clonal hematopoiesis of indeterminate potential (CHIP). I am currently serving as a Yale principle investigator for a number of clinical studies including industry-sponsored, cooperative group and investigator initiated trials looking at the efficacy of different novel agents for patients with malignant hematological conditions who otherwise have limited treatment options. I participate in hematology group of the Yale University Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center to study myeloid neoplasms with special interest in MPN.

Extensive Research Description

Management of Malignant Hematology - Older Adult Focus; Myeloprolipherative Neoplasms

Coauthors

Research Interests

Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders

Selected Publications

Clinical Trials

ConditionsStudy Title
Myeloid and Monocytic LeukemiaAn Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination With Anti-Leukemia Agents in Subjects With Acute Myeloid Leukemia
Leukemia, other; Myeloid and Monocytic LeukemiaA Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Myeloid and Monocytic LeukemiaAn Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Multiple MyelomaA Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Leukemia, not otherwise specified; Leukemia, otherBLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
Myeloid and Monocytic LeukemiaBLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
Multiple MyelomaA Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Myeloid and Monocytic LeukemiaThe PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Leukemia, otherPhase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia
Lymphoid LeukemiaA Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Leukemia, not otherwise specified; Leukemia, otherPhase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Lymphoid LeukemiaA Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Myeloid and Monocytic LeukemiaA Phase 1, Open-label, Dose Finding Study of CC-90009 in Subjects With Relapsed, Refractory Acute Myeloid Leukemia